DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Souid, A.-K.
Right arrow Articles by Bernstein, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Souid, A.-K.
Right arrow Articles by Bernstein, M. L.

Vol. 29, Issue 11, 1460-1466, November 2001

Blood Thiols Following Amifostine and Mesna Infusions, a Pediatric Oncology Group Study

Abdul-Kader Souid, Robert C. Fahey, Mehmet K. Aktas, Omer A. Sayin, Sara Karjoo, Gerald L. Newton, Peter D. Sadowitz, Ronald L. Dubowy, and Mark L. Bernstein

State University of New York, Upstate Medical University, Department of Pediatrics, Syracuse, New York (A.-K.S., M.K.A., O.A.S., S.K., P.D.S., R.L.D.); University of California, San Diego, Department of Chemistry and Biochemistry, La Jolla, California (R.C.F., G.L.N.); and Saint Justine Hospital, Department of Hematology Oncology, Montreal, Quebec, Canada (M.L.B.)

The Pediatric Oncology Group study for metastatic Ewing's sarcoma used amifostine and mesna with the alkylating agents. To determine the fate of combined drug thiols, we measured thiol levels in plasma, red blood cells (RBC), and peripheral blood mononuclear cells (PBMC) of four patients. We also conducted analogous measurements on two patients who received mesna alone and a volunteer's blood following in vitro treatment. Thiols were labeled with monobromobimane, separated on high-pressure liquid chromatography, and detected by fluorescence. Incubation of a volunteer's blood with mesna, WR-1065, or both revealed that cellular uptake of total reducible drug was ~10% of plasma level for mesna but ~60% for WR-1065. Cellular drugs were mainly the thiol form, whereas half of the plasma drugs were disulfides. Combined incubation with both thiols did not change the extent or form of uptake. WR-1065 and mesna prevented glutathione depletion by 4-hydroperoxycyclophosphamide. Results from patients were similar. WR-1065 and mesna appeared in the cells by the end of the drug infusions, although WR-1065 uptake was more efficient than mesna. The concentration-time profiles of mesna in RBC paralleled those in plasma. Amifostine administration during mesna infusion caused transient increase in mesna levels. Both agents increased blood cysteine and decreased total reducible cysteine. Mesna alone and mesna plus amifostine prevented cellular glutathione depletion. In conclusion, mesna is imported by RBC and PBMC, but less efficiently than WR-1065. When present at equal levels, these thiols do not influence each other's uptake. Adequate dosing of either drug is necessary for protecting the cells from toxic effects of alkylating agents.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J Clin PharmacolHome page
B. L. Urquhart, D. J. Freeman, J. D. Spence, and A. A. House
Mesna as a Nonvitamin Intervention to Lower Plasma Total Homocysteine Concentration: Implications for Assessment of the Homocysteine Theory of Atherosclerosis
J. Clin. Pharmacol., August 1, 2007; 47(8): 991 - 997.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. L. Bernstein, M. Devidas, D. Lafreniere, A.-K. Souid, P. A. Meyers, M. Gebhardt, K. Stine, R. Nicholas, E. J. Perlman, R. Dubowy, et al.
Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--A Report From the Children's Oncology Group
J. Clin. Oncol., January 1, 2006; 24(1): 152 - 159.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A.-K. Souid, R. L. Dubowy, S. M. Blaney, L. Hershon, J. Sullivan, W. D. McLeod, and M. L. Bernstein
Phase I Clinical and Pharmacologic Study of Weekly Cisplatin and Irinotecan Combined with Amifostine for Refractory Solid Tumors
Clin. Cancer Res., February 1, 2003; 9(2): 703 - 710.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur
U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid
Oncologist, October 1, 2002; 7(5): 393 - 400.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
P. D. Sadowitz, B. A. Hubbard, J. C. Dabrowiak, J. Goodisman, K. A. Tacka, M. K. Aktas, M. J. Cunningham, R. L. Dubowy, and A.-K. Souid
Kinetics of Cisplatin Binding to Cellular DNA and Modulations by Thiol-Blocking Agents and Thiol Drugs
Drug Metab. Dispos., February 1, 2002; 30(2): 183 - 190.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.